Related Experiment Video
Updated: May 4, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.5K
Cardiovascular gene therapy for myocardial infarction
Maria C Scimia1, Anna M Gumpert, Walter J Koch
1Temple University, Translational Medicine/Pharmacology , 3500 N. Broad Street, Philadelphia, 19140 , USA walter.koch@Temple.edu.
Expert Opinion on Biological Therapy
|December 17, 2013
Summary
Cardiovascular gene therapy targets ventricular dysfunction after myocardial infarction (MI). This review examines molecular targets for treating heart failure and atherosclerosis, emphasizing safety, expression, specificity, and efficacy (SESE).
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy is a significant area in cardiovascular disease research, accounting for 8.4% of trials in 2012.
- It aims to treat conditions like heart failure, peripheral artery disease, and atherosclerosis.
- Monogenic cardiovascular diseases, such as Fabry disease, are also targets for gene therapy.
Purpose of the Study:
- To review molecular targets for treating ventricular dysfunction post-myocardial infarction (MI).
- To address clinical consequences of MI, including heart failure and ischemia.
- To explore treatments for etiological causes of MI, such as atherosclerosis and graft disease.
Main Methods:
- Literature review focusing on molecular targets in cardiovascular gene therapy.
- Analysis of targets in clinical trials and developmental pipelines.
- Discussion of prerequisites for successful gene target therapy.
Main Results:
- Identified current and pipeline molecular targets for cardiovascular gene therapy.
- Highlighted the clinical consequences and etiological causes of MI as therapeutic focuses.
- Outlined the SESE criteria (safety, expression, specificity, efficacy) for gene target success.
Conclusions:
- Summarized key molecular targets for cardiovascular gene therapy.
- Emphasized the importance of the SESE criteria for successful therapeutic development.
- Provided an outlook on the future of gene therapy in treating cardiovascular diseases.
Related Concept Videos
00:59Gene Therapy
22.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
22.1K
00:59Gene Therapy
4.5K
4.5K
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
01:17Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790